Published On: Wed, Oct 19th, 2016

Cesca Therapeutics Inc. (KOOL) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of Cesca Therapeutics Inc. (KOOL).

Most recent broker ratings

12/22/2015 – Cesca Therapeutics Inc. was downgraded to “hold” by analysts at Maxim Group. They now have a USD 1 price target on the stock.

09/21/2015 – Cesca Therapeutics Inc. was upgraded to “buy” by analysts at H.C. Wainwright. They now have a USD 2 price target on the stock.

05/01/2015 – Cesca Therapeutics Inc. had its “sell” rating reiterated by analysts at Zacks.

01/02/2015 – Cesca Therapeutics Inc. had its “buy” rating reiterated by analysts at MKM Partners. They now have a USD 7 price target on the stock.

The share price of Cesca Therapeutics Inc. (KOOL) was up +0.00% during the last day of trading, with a day high of 3.27. 29121 shares were traded during the last session.

The stock’s 50 day moving average is 3.87 and its 200 day moving average is 3.44. The stock’s market capitalization is 29.96M. Cesca Therapeutics Inc. has a 52-week low of 1.60 and a 52-week high of 12.40.

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.